<DOC>
	<DOCNO>NCT00123890</DOCNO>
	<brief_summary>The purpose study determine eligibility one three treatment study CCR5 antagonist GW873140 observational study without GW873140 . No investigational treatment administer study .</brief_summary>
	<brief_title>Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 ( CCR5 ) Antagonist GW873140</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>HIVinfected . Screening viral load least 5000copies/mL . Total prior antiretroviral experience least 3 month document resistance least one drug follow class : nucleoside reverse transcriptase inhibitor ( NRTI ) , nonnucleoside reverse transcriptase inhibitor ( NNRTI ) , protease inhibitor ( PI ) , stable antiretroviral regimen ( antiretroviral treatment ) least 4 week screen . Able receive ritonavirboosted protease inhibitor treatment study . Women childbearing potential must use specific form contraception . Exclusion criterion : Acute laboratory abnormality . History pancreatitis hepatitis , hepatitis B hepatitis C coinfection , chronic liver disease . Screening liver function test use determine eligibility . Changes antiretroviral therapy 4 week prior screen Day 1 treatment observational study . Pregnancy breastfeed woman . Recent participation experimental drug trial . Prior use CCR5 CXCR4 antagonist . Significant ECG abnormalities significant history active pancreatitis , hepatitis , opportunistic infection , malabsorption disorder , cancer , severe illness . Current use certain medication may exclude participation study . Additional qualify criterion laboratory test requirement assess study physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>HIV-1 GW873140 CCR5 antagonist experience</keyword>
</DOC>